[1] Ferlay J, Shin HR, Bray F, et al. Estimates of worldwide burden of cancer in 2008:GLOBOCAN2008[J]. Int J Cancer, 2010, 127(12):2893-2917.  doi: 10.1002/ijc.25516
[2] Paulson AS, Tran Cao Hs, Tempero MA, et al. Therapeutic advances in pancreatic cancer[J]. Gastroenterology, 2013, 144(6):1316-1326.  doi: 10.1053/j.gastro.2013.01.078
[3] Yadav D, Lowenfels AB. The epidemiology of pancreatitis and pancreatic cancer[J]. Gastroenterology, 2013, 144(6):1252-1261.  doi: 10.1053/j.gastro.2013.01.068
[4] 王霞, 王晖, 张啸.胰腺癌中表观遗传修饰研究进展[J].世界华人消化杂志, 2010, 18(11):1141-1146.  doi: 10.3969/j.issn.1009-3079.2010.11.011
[5] Omura N, Goggins M. Epigenetics and epigenetic alterations in pancreatic cancer[J]. Int J Clin Exp Pathol, 2009, 2(4):310-326.
[6] 顾华丽, 田字彬. ras基因突变与肿瘤的关系[J].青岛大学医学院学报, 2005, 41(4):372-374.  doi: 10.3969/j.issn.1672-4488.2005.04.039
[7]

刘景生.细胞信息与调控[M].北京:中国协和医科大学出版社, 2004.
[8] 刘世英, 蒋宇扬, 曹健, 等.蛋白激酶C的抑制剂[J].科学通信, 2005, 50(5):405-415.
[9] Reuveni H, Livnah N, Geiger T, et al. Toward a PKB inhibitor:modification of a selective PKA inhibitor by rational design[J]. Biochemistry, 2002, 41(32):10304-10314.  doi: 10.1021/bi0202530
[10] 孙夕林, 王凯, 赵周社, 等. 18F标记表皮生长因子受体酪氨酸激酶抑制剂4-苯氨基-喹唑啉类方法进展[J].现代生物医学进展, 2014, 14(3):579-600.
[11] 孙夕林, 王凯, 李宏利, 等.分子影像技术在转化医学中的应用[J].现代生物医学进展, 2014, 14(2):377-382.
[12] Moore MJ, Goldstein D, Hamm J, et al. Erlotinib plus gemcitabine compared to gemcitabine alone in patients with advanced pancreatic cancer:A phase Ⅲ trial of the National Cancer Institute of Canada Clinical Trials Group[J]. J Clin Oncol, 2007, 25(15):1960-1966.  doi: 10.1200/JCO.2006.07.9525
[13] Hicks JW, Van Brocklin HF, Wilson AA, et al. Radiolabeled small molecule protein kinase inhibitors for imaging with PET and SPECT[J]. Molecules, 2010, 15(11):8260-8278.  doi: 10.3390/molecules15118260
[14] Poot AJ, Van Der Wildt B, Stigter-van Walsum M, et al. [11C]Sorafenib:radiosynthesis and preclinical evaluation in tumor-bearing mice of a new TKI-PET tracer[J]. Nucl Med Biol, 2013, 40(2):488-497.
[15] Vasdev N, LaRonde FJ, Woodgett JR, et al. Rationally designed PKA inhibitors for positron emissiontomography:synthesis and cerebral biodistributionofN-(2-(4-bromocinnamylamino)ethyl)-N-[11C]methyl-isoquinoline-5-sulfonamide[J]. Bioorg Med Chem, 2008, 16(9):5277-5284.  doi: 10.1016/j.bmc.2008.03.013
[16] Wang M, Xu L, Gao M, et al. [11C]enzastaurin, the first design and radiosynthesis of a new potential PET agent for imaging of protein kinase C[J]. Bioorg Med Chem Lett, 2011, 21(6):1649-1653.  doi: 10.1016/j.bmcl.2011.01.100